ESMO Press Releases

The ESMO Asia Congress 2020, the leading scientific platform in the Asia-Pacific region, will be held as a virtual meeting. 

The Molecular Analysis for Precision oncology (MAP) Congress is designed to answer the critical question about how to integrate the wealth of information coming from the analysis of tumour samples into daily practice.

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.

Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.

The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020. 

Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries

Data from latest research presented at the ESMO Virtual Congress 2020

The full scientific programme of the ESMO Congress 2020 (19-21 September) is now available online.

The European Society for Medical Oncology has announced the winners of the ESMO awards 2020.

Recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers are being launched today by ESMO

The science weekend of the ESMO Congress 2020 will be held as a virtual meeting between 19 and 21 September.